Exceptional Responders With Pancreatic Cancer to Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- 30
Summary
- Conditions
- Pancreatic Neoplasms
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is an observational study of patients with pancreatic cancer to identify genomic expression differences obtained from their circulating tumor cells between exceptional responders and non-responders to standard of care chemotherapy. This study requires a 10 mL heparinized peripheral blood sample...
This is an observational study of patients with pancreatic cancer to identify genomic expression differences obtained from their circulating tumor cells between exceptional responders and non-responders to standard of care chemotherapy. This study requires a 10 mL heparinized peripheral blood sample from each study participant at the time of enrollment to isolate, enrich and profile circulating tumor cells. Data analysis of the gene expression profile will define genomic patterns using Nearest Template Prediction for a predetermined panel of therapeutic agents based on standard of care. Chemotherapy selection is physician-choice. Information regarding disease progression will be gathered. Data analysis will be performed in study participants in the setting of ongoing disease progression.
Tracking Information
- NCT #
- NCT02555735
- Collaborators
- Memorial Sloan Kettering Cancer Center
- Weill Medical College of Cornell University
- The Pancreatic Cancer Treatment Center of Los Angeles
- Investigators
- Study Director: Brian McCarthy, PhD Adera Labs